Tenderwize
Retour à la recherche

Non-exclusive Drug Discount Agreement for Budesonide

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 337 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Budesonid (ATC-Code nach WHO: A07EA06)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No guaranteed minimum volumes; actual demand depends on prescription behavior, patient numbers, and pharmacy stockpilin...

Buyer reserves right to terminate Open-House early if exclusive discount agreements are concluded, which typically occu...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Non-exclusive drug discount agreements for Budesonide (ATC A07EA06) hard capsules 3 mg
  • Open-House model: all interested pharmaceutical companies can participate if they meet conditions
Afficher le résumé complet

Non-exclusive drug discount agreement under §130a Abs. 8 SGB V for Budesonide (ATC A07EA06) hard capsules 3 mg via Open-House model. Buyer: AOK PLUS for Saxony and Thuringia. No guaranteed volumes; contract ends 31.07.2027. First submission deadline 07.07.2025, later submissions possible. Confidentiality required. Estimated value not disclosed.

Risques

No guaranteed minimum volumes; actual demand depends on prescription behavior, patient numbers, and pharmacy stockpilin...

Buyer reserves right to terminate Open-House early if exclusive discount agreements are concluded, which typically occu...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with seat in EU/EEA

Eligibility

  • Submit exclusion declaration (no grounds under GWB §§123-124) and Russia sanctions declaration

Administrative

  • Access and use DTVP project room for documents; maintain confidentiality of documents

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified - open-house model accepts all qualified participants.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Budesonide

Single lot covering Budesonide hard capsules 3 mg. Open-House model, non-exclusive, no individual negotiations. Supply to AOK PLUS region Saxony/Thuringia. Contract duration until 31.07.2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jul 2025 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified - open-house model accepts all qualified participants.

Détails de la procédure

Date de publication
04 Jun 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
365261-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30